Zydus Lifesciences Limited has informed the Exchange regarding a press release dated Jun 11, 2025, titled "Zydus receives EIR for the API manufacturing facility at Ankleshwar".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has received the Establishment Inspection Report (EIR) from the US FDA for its Active Pharmaceutical Ingredient (API) manufacturing facility in Ankleshwar. The US FDA inspected the facility from March 10 to March 14, 2025, and classified the inspection as 'No Action Indicated' (NAI), which is the most favorable outcome. The US FDA has officially closed the inspection. The company disclosed this under SEBI's Listing Obligations and Disclosure Requirements Regulation 30.
This is a positive development for Zydus shareholders, as the NAI classification confirms the Ankleshwar API facility meets US FDA standards with no compliance issues, removing any regulatory overhang and supporting uninterrupted API supplies and future product approvals for the US market.